Johannesen Caroline Klint, Gideonse David, Osei-Yeboah Richard, Lehtonen Toni, Jollivet Ombeline, Cohen Rachel A, Urchueguía-Fornes Arantxa, Herrero-Silvestre María, López-Lacort Mónica, Kramer Rolf, Fischer Thea K, Heikkinen Terho, Nair Harish, Campbell Harry, van Boven Michiel
Department of Virus and Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen, Denmark.
Department of Clinical Research, North Zealand University Hospital, Capital Region, Denmark.
Lancet Reg Health Eur. 2025 Feb 5;51:101227. doi: 10.1016/j.lanepe.2025.101227. eCollection 2025 Apr.
Respiratory syncytial virus (RSV) can cause severe disease, notably among infants, older adults, and individuals with comorbidities. Non-systematic testing and differences in coding practices affect direct measures of the hospital disease burden. We aim to tackle this issue and estimate RSV-associated respiratory hospital admissions through time series modelling of hospital admissions.
The number of RSV hospital admissions in Denmark, England, Finland, the Netherlands, and Spain were estimated with attribution analyses, using age-specific respiratory tract infection (RTI) admissions combined with virological data, both from routinely collected healthcare data. Analyses covered the years 2016-2023.
The attributed incidence of RSV per 100,000 children 0-2 months ranged from 1715 in Denmark to 3842 in England. In older adults, substantial differences in the incidence of ICD-10 coded RSV hospitalisations were found, while the attributed RSV incidence was more comparable, ranging from approximately 100 per 100,000 in adults 65-74 years to 200 per 100,000 persons 75-84 years and 500 per 100,000 persons 85 years and older.
RSV-attributed time series exhibit a high degree of synchronicity between participating countries, suggesting that this method for attribution addresses the known issues with underdiagnosis and misclassification. In the older age groups, a substantial proportion of RTI hospitalisations is attributed to RSV, underscoring the relevance of RSV as a cause of severe respiratory infections.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement 101034339. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.
呼吸道合胞病毒（RSV）可引发严重疾病，尤其是在婴儿、老年人以及患有合并症的个体中。非系统性检测和编码方式的差异影响了对医院疾病负担的直接测量。我们旨在解决这一问题，并通过对医院入院数据进行时间序列建模来估计与RSV相关的呼吸道住院病例数。
利用归因分析估计丹麦、英格兰、芬兰、荷兰和西班牙的RSV住院病例数，将特定年龄的呼吸道感染（RTI）住院病例与病毒学数据相结合，二者均来自常规收集的医疗保健数据。分析涵盖2016年至2023年。
每10万名0至2个月大儿童的RSV归因发病率在丹麦为1715例，在英格兰为3842例。在老年人中，发现国际疾病分类第10版（ICD - 10）编码的RSV住院发病率存在显著差异，而归因的RSV发病率更具可比性，在65至74岁的成年人中约为每10万人100例，在75至84岁的人群中为每10万人200例，在85岁及以上的人群中为每10万人500例。
RSV归因时间序列在参与国家之间呈现出高度同步性，这表明这种归因方法解决了已知的漏诊和错误分类问题。在老年人群体中，相当一部分RTI住院病例归因于RSV，这凸显了RSV作为严重呼吸道感染病因的相关性。
本项目已获得创新药物倡议2联合事业的资助，资助协议编号为101034339。该联合事业得到了欧盟“地平线2020”研究与创新计划和欧洲制药工业协会联合会（EFPIA）的支持。
